DE69912635D1 - Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen - Google Patents

Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen

Info

Publication number
DE69912635D1
DE69912635D1 DE69912635T DE69912635T DE69912635D1 DE 69912635 D1 DE69912635 D1 DE 69912635D1 DE 69912635 T DE69912635 T DE 69912635T DE 69912635 T DE69912635 T DE 69912635T DE 69912635 D1 DE69912635 D1 DE 69912635D1
Authority
DE
Germany
Prior art keywords
olanzapine
disorder
oxide
treatment
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69912635T
Other languages
English (en)
Other versions
DE69912635T2 (de
Inventor
E Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69912635D1 publication Critical patent/DE69912635D1/de
Publication of DE69912635T2 publication Critical patent/DE69912635T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69912635T 1998-11-23 1999-11-22 Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen Expired - Fee Related DE69912635T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10955198P 1998-11-23 1998-11-23
US109551P 1998-11-23
PCT/US1999/027644 WO2000030649A1 (en) 1998-11-23 1999-11-22 Pharmaceutical compositions containing olanzapine-n-oxide

Publications (2)

Publication Number Publication Date
DE69912635D1 true DE69912635D1 (de) 2003-12-11
DE69912635T2 DE69912635T2 (de) 2004-05-13

Family

ID=22328264

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69912635T Expired - Fee Related DE69912635T2 (de) 1998-11-23 1999-11-22 Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen

Country Status (9)

Country Link
US (3) US6121259A (de)
EP (1) EP1135136B1 (de)
JP (1) JP2002530340A (de)
AT (1) ATE253364T1 (de)
AU (1) AU757870B2 (de)
CA (1) CA2351719A1 (de)
DE (1) DE69912635T2 (de)
ES (1) ES2211205T3 (de)
WO (1) WO2000030649A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
DK1575590T3 (da) 2002-12-27 2008-02-11 Otsuka Pharma Co Ltd Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser
WO2007137224A2 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Method of treatment
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
RU2470013C2 (ru) * 2007-04-12 2012-12-20 НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов
US9018202B2 (en) * 2010-12-03 2015-04-28 Allergan, Inc. Methods for treating diseases of the retina
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
MX2014011971A (es) 2012-04-04 2015-01-16 Ivax Int Gmbh Composiciones farmaceuticas para terapia de combinacion.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
WO1997011700A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Method for treating a tic disorder
JP2000502346A (ja) * 1995-12-21 2000-02-29 イーライ・リリー・アンド・カンパニー 皮膚炎の処置方法
EA000745B1 (ru) * 1995-12-22 2000-02-28 Эли Лилли Энд Компани Способ лечения депрессии
JP2000506859A (ja) * 1996-03-11 2000-06-06 イーライ・リリー・アンド・カンパニー 双極性障害の処置方法
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
WO1997033585A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating autism
PL328924A1 (en) * 1996-03-11 1999-03-01 Lilly Co Eli Method of treating abuse of substances
GB9615767D0 (en) * 1996-07-26 1996-09-04 Smithkline Beecham Plc Novel treatment

Also Published As

Publication number Publication date
WO2000030649A1 (en) 2000-06-02
AU1826600A (en) 2000-06-13
AU757870B2 (en) 2003-03-06
CA2351719A1 (en) 2000-06-02
EP1135136B1 (de) 2003-11-05
US6121259A (en) 2000-09-19
ATE253364T1 (de) 2003-11-15
JP2002530340A (ja) 2002-09-17
EP1135136A1 (de) 2001-09-26
ES2211205T3 (es) 2004-07-01
US20020065272A1 (en) 2002-05-30
US6352984B1 (en) 2002-03-05
DE69912635T2 (de) 2004-05-13

Similar Documents

Publication Publication Date Title
ATE253364T1 (de) Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
ATE286398T1 (de) Desmethylolanzapine enthaltende zusammensetzungen und verfahren
BRPI0413022A (pt) derivados de 3-amino cromado e 2-amino tetralina
FI963294A (fi) Naftyyliamidit keskushermostoaineina
ATE410157T1 (de) Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI0402420A (pt) Processos de toner
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
NO975198D0 (no) Tetralinforbindeler med MDR-aktivitet
DE60103927D1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DE69626393T2 (de) Spezifische oligonukleotide für hepatitis b virus
TR200101357T2 (tr) Parkinson hastalığı, ADHD ve mikroadenomların tedavisi için ilaçlar.
DE60027077D1 (de) Reinigungszusammensetzung zur Behandlung und/oder Verbesserung von Schuppen, Dermatitis seborrhoeica, Psoriasis und Ekzemen und deren Symptomen
DE60231507D1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
PT1047449E (pt) Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal
BRPI0400038A (pt) Reciclo de condensados excedentes do resfriamento em um processo para purificação de acrilonitrila
DE69808119T2 (de) Diskontinuierliches und kontinuierliches gegenstromstoffaustauschverfahren
Lee et al. Effects of School Safety Education on Safety Behavior among Elementary School Students.
JP2000319390A5 (de)
Laurent The scent of music
Mora Mesillaros and Gringo Mexicans: The changing meanings of race, nation, and space in Southern New Mexico, 1848–1912
유정 Narrative Intervention for Older Adults
Cha Discourse Functions of-kes kathta in Korean Conversation
Falkai Kausale Therapie der Schizophrenie möglich?
Fountoulakis et al. Treatment of bipolar disorder: a systematic review of available data

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee